Cited by 541Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Treatment and ManagementBlood Pressure and Hypertension Studies

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Ramipril and the Development of Diabetes

Open access

Yusuf, Salim·2001·JAMA

DOI 10.1001/jama.286.15.1882

Open this paper in CoChat — free account

Abstract

CONTEXT: Type 2 diabetes is a growing clinical and public health problem. Preventive efforts related to lifestyle modification are not always successful; therefore, alternative prevention strategies need to be studied. OBJECTIVE: To investigate the effectiveness of ramipril, an angiotensin-converting enzyme inhibitor, in preventing diabetes among high-risk persons. DESIGN, SETTING, AND PARTICIPANTS: The randomized, controlled Heart Outcomes Prevention Evaluation trial of 5720 patients older than 55 years without known diabetes but with vascular disease who were followed up for a mean of 4.5 years. The study included 267 hospitals in 19 countries and was conducted between 1994 and 1999. INTERVENTION: Patients were randomly assigned to receive ramipril, up to 10 mg/d (n = 2837), or placebo (n = 2883). MAIN OUTCOME MEASURE: Diagnosis of diabetes determined from self-report at follow-up visits every 6 months, compared between the 2 groups. RESULTS: One hundred and two individuals (3.6%) in the ramipril group developed diabetes compared with 155 (5.4%) in the placebo group (relative risk [RR], 0.66; 95% confidence interval [CI], 0.51-0.85, P<.001). Similar results were noted when different diagnostic criteria were used; in the ramipril group, the RR for diagnosis of diabetes and hemoglobin A(1c) greater than 110% was 0.60 (95% CI, 0.43-0.85), for initiation of glucose-lowering therapy, 0.56 (95% CI, 0.41-0.77), and for both, 0.51 (95% CI, 0.34-0.76). These effects were also consistently seen in several subgroups examined. CONCLUSIONS: Ramipril is associated with lower rates of new diagnosis of diabetes in high-risk individuals. Because these results have important clinical and public health implications, this hypothesis requires prospective confirmation.

Integrity signals

Registry

Crossref · 10.1001/jama.286.15.1882

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

The text we found for this paper looks like another document, so its claims and self-check weren’t run. The registry and citation checks still apply.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The text we found for this paper looks like another document, so the self-check wasn’t run.

The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07019-6 · Cited by 20,023
Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study
Pan, X.-R., Li, G.-W., Hu, Y.-H., Wang, J.-X., Yang, W.-Y., An, Z.-X., Hu, Z.-X., Juan-Lin, Xiao, J.-Z., Cao, H.-B., et al. (1997) · Diabetes Care · doi:10.2337/diacare.20.4.537 · Cited by 4,320
Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy
(2000) · The Lancet · doi:10.1016/s0140-6736(99)12323-7 · Cited by 3,179
Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial
Hansson, L., Lindholm, L. H., NISKANEN, L. K., Lanke, J., Hedner, T., Niklason, A., LUOMANMÄKI, K., Dahlöf, B., Fairé, U. D., Mörlin, C., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(98)05012-0 · Cited by 1,991
Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39
Stearne, M. R., Palmer, S. L., Hammersley, M. S., Franklin, S. L., Spivey, R. S., Lévy, J., Tidy, C. R., Bell, N. J., Steemson, J., Barrow, B. A., et al. (1998) · UCL Discovery (University College London) · Cited by 1,406
Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats
Carlsson, P., Berne, C., & Jansson, L. E. (1998) · Diabetologia · doi:10.1007/s001250050880 · Cited by 305

Show all 15 references

Sorted by citations

Items 201–300 of 540

Differing Effects of Antihypertensive Drugs on the Incidence of Diabetes Mellitus Among Patients With Hypertensive Kidney Disease
Thornley‐Brown, D. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.7.797 · Cited by 42
Inactivation of adipose angiotensinogen reduces adipose tissue macrophages and increases metabolic activity
LeMieux, M. J., Ramalingam, L., Mynatt, R. L., Kalupahana, N. S., Kim, H. J., & Moustaïd‐Moussa, N. (2015) · Obesity · doi:10.1002/oby.21352 · Cited by 41
Effects of telmisartan on metabolic syndrome components: a comprehensive review
Imenshahidi, M., Roohbakhsh, A., & Hosseinzadeh, H. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116169 · Cited by 46
Clinical characteristics, process of care, and outcomes of Hispanic patients presenting with non–ST-segment elevation acute coronary syndromes: Results from Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines (CRUSADE)
Cohen, M. G., Roe, M. T., Mulgund, J., Peterson, E. D., Sonel, A. F., Menon, V., Smith, S. C., Saucedo, J. F., Lytle, B. L., Pollack, C. V., et al. (2006) · American Heart Journal · doi:10.1016/j.ahj.2005.09.003 · Cited by 40
Prevention of type 2 diabetes: data from recent trials
Kanaya, A. M., & Narayan, K. M. V. (2003) · Primary Care Clinics in Office Practice · doi:10.1016/s0095-4543(03)00034-4 · Cited by 39
A Noninferiority Comparison of Valsartan/Hydrochlorothiazide Combination Versus Amlodipine in Black Hypertensives
Weir, M. R., Ferdinand, K. C., Flack, J. M., Jamerson, K., Daley, W. L., & Zelenkofske, S. L. (2005) · Hypertension · doi:10.1161/01.hyp.0000180457.82483.6b · Cited by 39
Lewis K. Dahl Memorial Lecture
Diz, D. I. (2008) · Hypertension · doi:10.1161/hypertensionaha.107.108985 · Cited by 38
Second World Congress on the Insulin Resistance Syndrome
Bloomgarden, Z. T. (2005) · Diabetes Care · doi:10.2337/diacare.28.7.1821 · Cited by 37
Pharmacologic Approaches to the Prevention of Type 2 Diabetes in High Risk Pediatric Patients
Freemark, M. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021033 · Cited by 36
Risk factor assessment for new onset diabetes: literature review
Bakris, G. L., Stockert, J., Molitch, M. E., Zhou, Q., Champion, A., Bacher, P. H., Sowers, J. R., & on behalf of the STAR Investigators (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00925.x · Cited by 36
Type 2 Diabetes Mellitus and Heart Failure
Choy, C. K., Rodgers, J. E., Nappi, J. M., & Haines, S. T. (2008) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.28.2.170 · Cited by 34
Best Strategies for Hypertension Management in Type 2 Diabetes and Obesity
Allcock, D. M., & Sowers, J. R. (2010) · Current Diabetes Reports · doi:10.1007/s11892-010-0100-z · Cited by 35
From Sea to Shining Sea and the Great Plains to Patagonia: A Review on Current Knowledge of Diabetes Mellitus in Hispanics/Latinos in the US and Latin America
Avilés-Santa, L. M., Colón‐Ramos, U., Lindberg, N. M., Mattei, J., Pasquel, F. J., & Pérez, C. M. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00298 · Cited by 38
ACE and Type 2 Diabetes Risk: A Mendelian Randomization Study
Pigeyre, M., Sjaarda, J., Chong, M., Hess, S., Bosch, J., Yusuf, S., Gerstein, H. C., & Paré, G. (2020) · Diabetes Care · doi:10.2337/dc19-1973 · Cited by 34
Self-citation
Effects of Telmisartan on Glucose Levels in People at High Risk for Cardiovascular Disease but Free From Diabetes
Barzilay, J. I., Gao, P., Rydén, L., Schumacher, H., Probstfield, J. L., Commerford, P., Dans, A., Ferreira, R., Keltai, M., Paolasso, E., et al. (2011) · Diabetes Care · doi:10.2337/dc11-0545 · Cited by 35
Self-citation
National Pharmacy Cardiovascular Council Treatment Guidelines for the Management of Type 2 Diabetes Mellitus: Toward Better Patient Outcomes and New Roles for Pharmacists
Hawkins, D., Bradberry, J. C., Cziraky, M. J., Talbert, R. L., Bartels, D. W., & Cerveny, J. D. (2002) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.22.7.436.33667 · Cited by 35
The importance of β-cell management in type 2 diabetes
Standl, E. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01360.x · Cited by 34
Renin–angiotensin-system blockade in the prevention of diabetes
Östergren, J. (2007) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2007.01.018 · Cited by 34
Effects of ACE-inhibition on IGF-1 and IGFBP-3 concentrations in older adults with high cardiovascular risk profile
Giovannini, S., Cesari, M., Marzetti, E., Leeuwenburgh, C., Maggio, M. G., & Pahor, M. (2010) · The journal of nutrition health & aging · doi:10.1007/s12603-010-0036-7 · Cited by 34
Prevention and current onset delay approaches of type 2 diabetes mellitus (T2DM)
Souto, S. B., Souto, E. B., Braga, D. C., & Medina, J. L. (2011) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-011-1038-z · Cited by 36
A Selective Peroxisome Proliferator-Activated Receptor-γ Modulator, Telmisartan, Binds to the Receptor in a Different Fashion from Thiazolidinediones
Tagami, T., Yamamoto, H., Moriyama, K., Sawai, K., Usui, T., Shimatsu, A., & Naruse, M. (2009) · Endocrinology · doi:10.1210/en.2008-0502 · Cited by 35
Erratum to: Bedtime ingestion of hypertension medications reduces the risk of new-onset type 2 diabetes: a randomised controlled trial
Hermida, R. C., Ayala, D. E., Mojón, A., & Fernández, J. R. (2015) · Diabetologia · doi:10.1007/s00125-015-3806-2 · Cited by 33
A truly deadly quartet: obesity, hypertension, hypertriglyceridemia, and hyperinsulinemia.
Nambi, V., Hoogwerf, B. J., & Sprecher, D. L. (2002) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.69.12.985 · Cited by 31
The effects of telmisartan and amlodipine on metabolic parameters and blood pressure in type 2 diabetic, hypertensive patients
Negro, R., & Hassan, H. (2006) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.3317/jraas.2006.045 · Cited by 32
Diabetes and Heart Disease: An Evidence-Driven Guide to Risk Factors Management in Diabetes
Lteif, A., Mather, K., & Clark, C. (2003) · Cardiology in Review · doi:10.1097/01.crd.0000086892.07437.05 · Cited by 35
New approaches in the intensive management of cardiovascular risk in the metabolic syndrome
Rosenson, R. S. (2005) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2004.10.001 · Cited by 31
Strategies in ongoing clinical trials to reduce cardiovascular disease in patients with diabetes mellitus and insulin resistance
Mazzone, T. (2004) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.02.003 · Cited by 32
Beyond the classic angiotensin-receptor-blocker profile
Kurtz, T. W. (2008) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio0805 · Cited by 31
The kallikrein‐kinin system, angiotensin converting enzyme inhibitors and insulin sensitivity
Damas, J., Garbacki, N., & Lefèbvre, P. J. (2004) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.489 · Cited by 31
Can type 2 diabetes mellitus be considered preventable?
Jermendy, G. (2005) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2005.03.010 · Cited by 30
Differential effect of β‐blocker therapy on insulin resistance as a function of insulin sensitizer use: results from GEMINI
Fonseca, V. A., Bakris, G. L., Bell, D. S. H., McGill, J. B., Raskin, P., Messerli, F. H., Phillips, R. A., Katholi, R. E., Wright, J. T., Waterhouse, B. R., et al. (2007) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02151.x · Cited by 29
Preventing Type 2 Diabetes Mellitus
Curtis, J., & Wilson, C. (2005) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.18.1.37 · Cited by 28
Mechanisms of cardiovascular risk reduction with ramipril: insights from HOPE and HOPE substudies
Lonn, E. (2003) · European Heart Journal Supplements · doi:10.1016/s1520-765x(03)90063-0 · Cited by 29
Hypertension and the Kidney
Wiederkehr, M. R., Toto, R. D., Fenves, A. Z., & Ram, C. V. S. (2005) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2005.02.008 · Cited by 28
Metabolic Syndrome and Prediabetes
Babu, A. R., & Fogelfeld, L. A. (2006) · Disease-a-Month · doi:10.1016/j.disamonth.2006.03.001 · Cited by 27
Sympathoexcitation Associated with Renin‐Angiotensin System in Metabolic Syndrome
Kishi, T., & Hirooka, Y. (2013) · International Journal of Hypertension · doi:10.1155/2013/406897 · Cited by 26
Anti‐diabetic effect of blockade of the renin‐angiotensin system
Ando, K., & Fujita, T. (2005) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2005.00526.x · Cited by 27
Pathogenesis, Risk Assessment and Prevention of Type 2 Diabetes mellitus
Joost, H. (2008) · Obesity Facts · doi:10.1159/000137673 · Cited by 27
Kidney and related chronic disease profiles and risk factors in three remote Australian Aboriginal communities
Hoy, W. E., Kondalsamy‐Chennakesavan, S., Scheppingen, J., & Sharma, S. (2005) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2004.10.004 · Cited by 27
The role of renin–angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: are all the angiotensin receptor blockers equal?
Karagiannis, A. I., Mikhailidis, D. P., Athyros, V. G., Kakafika, A. I., Τζιόμαλος, Κ., Liberopoulos, E. N., Florentin, M., & Elisaf, M. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.2.191 · Cited by 28
Dysmetabolic Syndrome: Multiple Risk Factors for Premature Adult Disease in an Adolescent Girl
Falkner, B. E., Hassink, S. G., ROSS, J. L., & Gidding, S. S. (2002) · PEDIATRICS · doi:10.1542/peds.110.1.e14 · Cited by 27
Suppression of lipoprotein lipase expression in 3T3-L1 cells by inhibition of adipogenic differentiation through activation of the renin-angiotensin system
Saiki, A., Koide, N., Watanabe, F., Murano, T., Miyashita, Y., & Shirai, K. (2008) · Metabolism · doi:10.1016/j.metabol.2008.03.014 · Cited by 26
Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderly
Jugdutt, B. I. (2010) · Clinical Interventions in Aging · doi:10.2147/cia.s6709 · Cited by 26
The association between circulating angiotensin-converting enzyme and cardiovascular risk in the elderly: a cross-sectional study
Ljungberg, L. U., Alehagen, U., Länne, T., Björck, H. M., Basso, R. D., Dahlström, U., & Persson, K. (2011) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320310391326 · Cited by 26
The renin angiotensin system as a therapeutic target to prevent diabetes and its complications
Vijayaraghavan, K., & DEEDWANIA, P. C. (2005) · Cardiology Clinics · doi:10.1016/j.ccl.2004.11.003 · Cited by 24
Treatment of cardiovascular dysfunction associated with the metabolic syndrome and type 2 diabetes
Oltman, C. L., Kleinschmidt, T. L., Davidson, E. P., Coppey, L. J., Lund, D. D., & Yorek, M. A. (2007) · Vascular Pharmacology · doi:10.1016/j.vph.2007.11.005 · Cited by 25
Angiotensin-receptor blocking agents and the peroxisome proliferator-activated receptor-γ system
Tuck, M. L. (2005) · Current Hypertension Reports · doi:10.1007/s11906-005-0019-y · Cited by 25
The metabolic syndrome: Diagnosis and treatment
Zieve, F. J. (2004) · Clinical cornerstone · doi:10.1016/s1098-3597(04)80093-0 · Cited by 26
Facts and Ideas from Anywhere
Roberts, W. C. (2004) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2004.11927961 · Cited by 25
Delaying the Onset of Type 2 Diabetes Mellitus in Patients with Prediabetes
Irons, B. K., Mazzolini, T. A., & Greene, R. S. (2004) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.24.4.362.33170 · Cited by 25
Efficacy of folic acid and enalapril combined therapy on reduction of blood pressure and plasma glucose: A multicenter, randomized, double-blind, parallel-controlled, clinical trial
Mao, G., Hong, X., Xing, H., Liu, P., Liu, H., Yu, Y., Zhang, S., Jiang, S., Wang, X., & Xu, X. (2008) · Nutrition · doi:10.1016/j.nut.2008.05.009 · Cited by 23
Metabolic syndrome and other factors associated with increased risk of diabetes
Streja, D. A. (2004) · Clinical cornerstone · doi:10.1016/s1098-3597(04)80094-2 · Cited by 23
Insulin resistance: a global epidemic in need of effective therapies
Califf, R. M. (2003) · European Heart Journal Supplements · doi:10.1016/s1520-765x(03)90045-9 · Cited by 23
Prevalence and risk factors associated with prediabetes and undiagnosed diabetes in France: The national CONSTANCES cohort
Lailler, G., Fuentes, S., Kab, S., Piffaretti, C., Guion, M., Czernichow, S., Cosson, E., & Fosse‐Edorh, S. (2022) · Diabetes Epidemiology and Management · doi:10.1016/j.deman.2022.100121 · Cited by 25
Association of KCNJ1 variation with change in fasting glucose and new onset diabetes during HCTZ treatment
Karnes, J., McDonough, C., Gong, Y., Vo, T., Langaee, T., Chapman, A., Gums, J., Beitelshees, A., Bailey, K., Del-Aguila, J., et al. (2012) · The Pharmacogenomics Journal · doi:10.1038/tpj.2012.34 · Cited by 21
Angiotensin converting enzyme inhibitors for prevention of new-onset type 2 diabetes mellitus: A meta-analysis of 72,128 patients
Geng, D.-F., Jin, D., Wu, W., Liang, Y.-D., & Wang, J. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.06.125 · Cited by 22
Update on the Prevention of Type 2 Diabetes
Karam, J. G., & McFarlane, S. I. (2010) · Current Diabetes Reports · doi:10.1007/s11892-010-0163-x · Cited by 22
Independent Association of Serum Aldosterone Level with Metabolic Syndrome and Insulin Resistance in Korean Adults
Min, S. H., Kim, S., Jeong, I., Cho, H., Jeong, J., Lee, J., Kang, H., Kim, H.-S., Park, K. S., & Lim, S. K. (2017) · Korean Circulation Journal · doi:10.4070/kcj.2017.0200 · Cited by 22
Antihypertensive drugs and incidence of type 2 diabetes: Evidence and implications for clinical practice
Asfaha, S., & Padwal, R. S. (2005) · Current Hypertension Reports · doi:10.1007/s11906-005-0063-7 · Cited by 22
Physiology, Genetics, and Cardiovascular Disease: Focus on African Americans
Gibbons, G. H. (2004) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2004.03562.x · Cited by 22
Second World Congress on the Insulin Resistance Syndrome
Bloomgarden, Z. T. (2005) · Diabetes Care · doi:10.2337/diacare.28.8.2073 · Cited by 22
ACE Inhibitors and Angiotensin Receptor Antagonists and the Incidence of New-Onset Diabetes Mellitus
Aguilar, D. A., & Solomon, S. D. (2006) · Drugs · doi:10.2165/00003495-200666090-00001 · Cited by 22
Role of inflammatory pathways in the development and cardiovascular complications of type 2 diabetes
Huerta, M. G., & Nadler, J. L. (2002) · Current Diabetes Reports · doi:10.1007/s11892-002-0103-5 · Cited by 22
Therapeutic approaches in the prevention of cardiovascular disease in metabolic syndrome and in patients with type 2 diabetes
Rosenson, R. S., & Reasner, C. A. (2004) · Current Opinion in Cardiology · doi:10.1097/01.hco.0000133111.66486.c6 · Cited by 21
Comparing six antihypertensive medication classes for preventing new‐onset diabetes mellitus among hypertensive patients: a network meta‐analysis
Yang, Y., & Xu, H. (2017) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13096 · Cited by 22
Antihypertensive treatment and new-onset diabetes mellitus
Aksnes, T. A., Reims, H. M., Kjeldsen, S. E., & Mancia, G. (2005) · Current Hypertension Reports · doi:10.1007/s11906-005-0029-9 · Cited by 21
Vascular and metabolic effects of angiotensin II receptor blockers
Barra, S., Vitagliano, A., Cuomo, V., Vitagliano, G., & Gaeta, G. B. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560802653180 · Cited by 21
Should the Insulin Resistance Syndrome be Treated in the Elderly?
Grant, R. W., & Meigs, J. B. (2004) · Drugs & Aging · doi:10.2165/00002512-200421030-00001 · Cited by 21
Drug Therapy in Transplant Recipients
Bernardo, J. F., & McCauley, J. (2004) · Drugs & Aging · doi:10.2165/00002512-200421050-00004 · Cited by 21
Cost Effectiveness of Ramipril in Patients at High Risk for Cardiovascular Events
Schädlich, P. K., Brecht, J. G., Rangoonwala, B., & Huppertz, E. (2004) · PharmacoEconomics · doi:10.2165/00019053-200422150-00001 · Cited by 21
The Role of Renin-Angiotensin Agents in Altering the Natural History of Type 2 Diabetes Mellitus
Lardizabal, J. A., & DEEDWANIA, P. C. (2010) · Current Cardiology Reports · doi:10.1007/s11886-010-0138-1 · Cited by 20
Association of angiotensin converting enzyme gene I/D polymorphism with type 2 diabetes mellitus.
Yang, M., Qiu, C., Xu, Q., & Hong-ding, X. (2006) · PubMed · Cited by 20
Quinapril
Culy, C. R., & Jarvis, B. (2002) · Drugs · doi:10.2165/00003495-200262020-00009 · Cited by 20
Metabolic Properties of Vasodilating β Blockers: Management Considerations for Hypertensive Diabetic Patients and Patients With the Metabolic Syndrome
Jacob, S., & Henriksen, E. J. (2004) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2004.03704.x · Cited by 20
Candesartan for the treatment of hypertension and heart failure
Östergren, J. (2004) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.5.7.1589 · Cited by 20
The Effect of Antihypertensive Agents on New-Onset Diabetes Mellitus
Aksnes, T. A., Kjeldsen, S. E., & Mancia, G. (2006) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200606030-00001 · Cited by 19
The Metabolic Syndrome and Cardiometabolic Risk: Scope of the Problem and Current Standard of Care
Lender, D., & Clough, S. S. (2006) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.26.5part2.3s · Cited by 19
Opposing Effects of β Blockers and Angiotensin-Converting Enzyme Inhibitors on Development of New-Onset Diabetes Mellitus in Patients With Stable Coronary Artery Disease
Vardeny, O., Uno, H., Braunwald, E., Rouleau, J. L., Gersh, B. J., Maggioni, A. P., DOMANSKI, M. J., Pfeffer, M. A., & Solomon, S. D. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.01.064 · Cited by 19
Type 2 diabetes in people of South Asian origin: potential strategies for prevention
Chowdhury, T. A., & Hitman, G. A. (2007) · The British Journal of Diabetes · doi:10.1177/14746514070070060401 · Cited by 18
Update on the metabolic syndrome: Hypertension
Reynolds, K., & Wildman, R. P. (2009) · Current Hypertension Reports · doi:10.1007/s11906-009-0026-5 · Cited by 18
Metformin and vascular protection: a cardiologist's view
Libby, P. (2003) · Diabetes & Metabolism · doi:10.1016/s1262-3636(03)72796-7 · Cited by 18
The effect of antihypertensive drugs and drug combinations on the incidence of new‐onset type‐2 diabetes mellitus
Burke, T. A., Sturkenboom, M., Ohman‐Strickland, P., Wentworth, C. E., & Rhoads, G. G. (2007) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1444 · Cited by 19
Effect of sacubitril/valsartan and ACEI/ARB on glycaemia and the development of diabetes: a systematic review and meta-analysis of randomised controlled trials
Wang, R., Ye, H., Zhao, Y., Wei, J., Wang, Y., Zhang, X., & Wang, L. (2022) · BMC Medicine · doi:10.1186/s12916-022-02682-w · Cited by 20
Impact of TCF7L2 single nucleotide polymorphisms on hydrochlorothiazide-induced diabetes
Karnes, J. H., Gong, Y., Pacanowski, M. A., McDonough, C. W., Arwood, M. J., Langaee, T. Y., Pepine, C. J., Johnson, J. A., & Cooper‐DeHoff, R. M. (2013) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000012 · Cited by 17
Renin-angiotensin system activation in renal adipogenesis
Sui, Y., Zhao, H., Fan, R., Guan, J. Z., He, L., Lee, H. M., Chan, J. C. N., & Tong, P. C. Y. (2009) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00445.2009 · Cited by 17
Dietary Fat Intake Modulates Effects of a Frequent ACE Gene Variant on Glucose Tolerance with association to Type 2 Diabetes
Schüler, R., Osterhoff, M. A., Frahnow, T., Möhlig, M., Spranger, J., Stefanovski, D., Bergman, R. N., Li, X., Seltmann, A., Kabisch, S., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-08300-7 · Cited by 19
Myocardial Insulin Resistance: An Overview of Its Causes, Effects, and Potential Therapy
Toit, E. F. D., & Donner, D. G. (2012) · InTech eBooks · doi:10.5772/50619 · Cited by 18
Prevention of type 2 diabetes mellitus with angiotensin-converting-enzyme inhibitors
Solski, L., & Longyhore, D. S. (2008) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp070388 · Cited by 17
HIGH-RISK AFRICAN AMERICANS WITH MULTIPLE RISK FACTORS FOR CARDIOVASCULAR DISEASE: CHALLENGES IN PREVENTION, DIAGNOSIS, AND TREATMENT
Williams, R. A., Gavin, J. R., Phillips, R. A., Sumner, A. E., Duncan, A. K., Hollar, D., & Hennekens, C. H. (2006) · PubMed · doi:10.13016/vhfj-pelm · Cited by 17
Preventing diabetes by treating aspects of the metabolic syndrome
Sathyaprakash, R., & Henry, R. R. (2002) · Current Diabetes Reports · doi:10.1007/s11892-002-0106-2 · Cited by 17
ACE inhibition may decrease diabetes risk by boosting the impact of bradykinin on adipocytes
McCarty, M. F. (2003) · Medical Hypotheses · doi:10.1016/s0306-9877(02)00234-7 · Cited by 17
Telmisartan and cardioprotection
McFarlane, S. (2011) · Vascular Health and Risk Management · doi:10.2147/vhrm.s9447 · Cited by 17
Peroxisome proliferator activated receptor gamma and its activation in the treatment of insulin resistance and atherosclerosis: issues and opportunities
Beckman, J. A., Raji, A., & Plutzky, J. (2003) · Current Opinion in Cardiology · doi:10.1097/00001573-200311000-00009 · Cited by 16
The angiotensin II receptor antagonist valsartan enhances lipoprotein lipase mass in preheparin serum in type 2 diabetes with hypertension
Saiki, A., Ohira, M., Endo, K., Koide, N., Oyama, T., Murano, T., Miyashita, Y., & Shirai, K. (2006) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2006.04.004 · Cited by 16
Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure — Assessment of Reduction in Mortality and morbidity (CHARM) programme
Östergren, J. (2006) · Journal of Hypertension · doi:10.1097/01.hjh.0000220400.08128.fa · Cited by 16
Mechanistic and Clinical Aspects of Renin-Angiotensin-Aldosterone System Blockade in the Prevention of Diabetes Mellitus and Cardiovascular Disease
Hershon, K. S. (2011) · Endocrine Practice · doi:10.4158/ep10106.ra · Cited by 16
Association of angiotensin-II levels with albuminuria in subjects with normal glucose metabolism, prediabetes, and type 2 diabetes mellitus
Min, S. H., Kong, S. H., Lee, J.-E., Lee, D., Oh, T. J., Kim, K. M., Park, K. S., Jang, H. C., & Lim, S. K. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2017.07.002 · Cited by 15
Treatment of hypertension in individuals with the cardiometabolic syndrome: role of an angiotensin II receptor blocker, telmisartan
Francischetti, E. A., Celoria, B. M. J., Francischetti, A., & Genelhu, V. A. (2008) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.6.3.289 · Cited by 15
Fixed-dose manidipine/delapril versus losartan/hydrochlorothiazide in hypertensive patients with type 2 diabetes and microalbuminuria
Kohlmann, O., Roca-Cusachs, A., Laurent, S., Schmieder, R. E., Wenzel, R. R., & Fogari, R. (2009) · Advances in Therapy · doi:10.1007/s12325-009-0015-8 · Cited by 15
Type 2 diabetes and atherosclerotic cardiovascular disease: do they share common antecedents?
Krentz, A. J. (2002) · The British Journal of Diabetes · doi:10.1177/14746514020020050501 · Cited by 15

Authors: Yusuf, S.
Affiliations: Hamilton General Hospital (CA)
Corresponding author: Yusuf, Salim
ORCID: Yusuf, Salim
Venue: JAMA
Publisher: American Medical Association (AMA)
Published: 2001-10-17
Volume: 286
Issue: 15
Pages: 1882
ISSN: 0002-9955 (ISSN-L)
0098-7484
DOI: 10.1001/jama.286.15.1882
OpenAlex: W1980567021
Cited by: 541
References: 15
Citations by year: 2026: 3 · 2025: 1 · 2024: 10 · 2023: 1 · 2022: 3 · 2021: 4 · 2020: 4 · 2019: 7 · 2018: 4 · 2017: 12 · 2016: 5 · 2015: 12 · 2014: 10 · 2013: 15 · 2012: 21
FWCI: 33.55
Type: journal article
Language: en
Open access: green
cris.maastrichtuniversity.nl
Licence: other-oa
Locations: JAMA (publishedVersion)
PubMed (publishedVersion)
Research Publications (Maastricht University) (submittedVersion, other-oa)
University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
Keywords: ramipril, type 2 diabetes prevention, ACE inhibitors, diabetes incidence, high-risk patients, vascular disease, older adults, glucose-lowering therapy, HbA1c
MeSH terms: Aged, Angiotensin-Converting Enzyme Inhibitors, Cardiovascular Diseases, Diabetes Mellitus, Female, Humans, Male, Middle Aged, Proportional Hazards Models, Survival Analysis, Randomized Controlled Trials as Topic, Ramipril

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Ramipril and the Development of Diabetes

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks